Prosecution Insights
Last updated: November 04, 2026

Turning Point Therapeutics Inc.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days

Analysis

Turning Point Therapeutics Inc. is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is handled by a distinct examiner and 1 distinct art unit. The current prosecution effort is consolidated under this examiner, indicating a highly specific focus for the company's current patent efforts.

MARTIN, KEVIN STEPHEN is the busiest examiner for the company, responsible for the busiest examiner pending office action. This matter represents the company's current active pipeline in the pharmaceutical sector. The concentration of the portfolio under a single examiner allows for a direct and consistent dialogue during the prosecution of the technology.

Practitioners should note that the alignment of the pending matter within the specified technology area ensures that the examination is conducted by a specialist in biotechnology and pharmaceuticals. The focus on a single examiner and art unit provides a streamlined prosecution environment. This structure minimizes the complexity often associated with managing multiple examiner relationships across different technical units at the USPTO.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
MARTIN, KEVIN STEPHEN 1 77.0% +20.7%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18698692 SYNTHESIS OF MACROYCLIC COMPOUNDS MARTIN, KEVIN STEPHEN —

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18698692 SYNTHESIS OF MACROYCLIC COMPOUNDS MARTIN, KEVIN STEPHEN —

Top Art Units

Art UnitApps
1624 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18698692 SYNTHESIS OF MACROYCLIC COMPOUNDS MARTIN, KEVIN STEPHEN 1624 §103§112 Non-Final OA — Pending Apr 04, 2024

Managing Turning Point Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Turning Point Therapeutics Inc. have?

Turning Point Therapeutics Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Turning Point Therapeutics Inc. applications?

Kevin Stephen Martin has the most, with 1 of Turning Point Therapeutics Inc.'s pending office actions.

What technology area are Turning Point Therapeutics Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month